News|Podcasts|February 27, 2026

The Ron Lanton Report: Is Healthcare Consolidation Reaching Its Limits?

The episode will explore structural implications for supply chains, distribution models, and international strategy—not a political discussion, but a forward-looking planning lens.

This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a structural limit. For years, industry strategy has assumed continued consolidation across health systems, purchasing organizations, and distribution channels, driving efficiency through scale, centralized purchasing, and simplified contracting.

The discussion explores how even modest fragmentation could reshape supply chains, contracting dynamics, and distribution predictability. If consolidation slows, manufacturers and distributors may face more complex contracting environments, more distributed negotiating leverage, and less centralized purchasing behavior.

The episode also considers the international implications, including how changes in the U.S. healthcare structure could influence global launch strategies, pricing assumptions, and cross-border reference pricing systems.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.